BridgeBio Pharma (BBIO) Interest & Investment Income (2018 - 2026)

BridgeBio Pharma has reported Interest & Investment Income for 9 years, with the latest figure at $6.2 million in Q1 2026.

• Quarterly Interest & Investment Income rose 15.99% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.8 million (up 25.9% YoY) and the FY2025 annual result came in at $19.9 million, up 15.1% from the prior year.
• Interest & Investment Income climbed to $6.2 million in Q1 2026 per BBIO's latest filing, from $4.3 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $6.2 million in Q1 2026 and troughed at -$251000.0 in Q1 2022.
• A 5-year average of $2.7 million and a median of $3.3 million in 2024 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income slumped 147.31% in 2022, then soared 18668.97% in 2025.
• Over 5 years, Interest & Investment Income stood at $4.1 million in 2022, then jumped by 36.31% to $5.6 million in 2023, then slipped by 16.05% to $4.7 million in 2024, then declined by 7.5% to $4.3 million in 2025, then jumped by 44.18% to $6.2 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $6.2 million, $4.3 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.